ClinicalTrials.gg
TerminatedNCT04046328Updated Jul 19, 2022Results posted

Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome

A Phase 2 interventional study of Enteric-Coated Cholestyramine (ECC) Capsule and Placebo in Short Bowel Syndrome, sponsored by Pharmascience Inc.. Terminated at 3 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Pharmascience Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Difficult recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Short Bowel Syndrome with a site in Poland — 3 open to participants now, 5 under way, 4 of them phase 3. Short Bowel Syndrome · Poland.

Enrollment
14th of 15
13 · median 86
Started
2019
with 1 other
Phase 2
2 of 15
1 open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Pharmascience Inc.

Among the 15 studies in Short Bowel Syndrome with a site in Poland, this one is the 14th largest by enrollment, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 8th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

3 of the 15 studies in Short Bowel Syndrome with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Short Bowel Syndrome with a site in Poland, or all of them as a file.
02

Study summary

A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS) in adults. The formulation is expected to release cholestyramine in the remaining segment of the small intestine in SBS patients, thus binding bile acids after fat digestion, but before induction of diarrhea in the colon. The delayed-release profile is also expected to help reduce the potential for drug-drug interactions occurring in the proximal small intestine. Two doses of ECC will be studied for efficacy, safety and tolerability in this Phase IIa trial.

Read the detailed description

A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS). SBS is usually caused by the significant resection or loss of function of the ileum, leading to reduced reabsorption of bile acids and subsequent osmotic diarrhea. The new ECC formulation could release cholestyramine in the remaining segment of the small intestine in SBS patients, delivering and binding bile acids before they induce diarrhea in the colon. The proposed advantages of this formulation are: a) to prevent drug-drug interactions in the proximal GI tract, b) to preserve the fat digestive properties of bile acids in the duodenum and 3) to offer a more palatable dosage form to patients. Moreover, since distal delivery of cholestyramine is expected to be more effective in diarrhea prevention/reduction in SBS, lower doses than the ones used with non-enteric coated cholestyramine may be sufficient. Two doses of ECC will be studied for efficacy, safety and tolerability in well-defined non fully-colectomized, adult SBS patients suffering from diarrhea.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult, ambulatory male and female subjects
  2. Provision of signed and dated form (ICF)
  3. Age ≥ 18 years and ≤ 80 years
  4. Stable SBS of:

    1. Non-surgical origin; OR
    2. Surgical origin where the last surgical ileal resection was performed at least 6 months prior to enrolment
  5. Partial, Home Parenteral Nutrition and/or parenteral fluids are allowed, at a maximum frequency of 6 times a week throughout the trial, as long as the regimen has been stable for at least 2 weeks prior to screening and is expected to remain unchanged during the study
  6. At least 50 % of the colon being intact
  7. Intact duodenum
  8. ≥ 18
  9. Presence of stable chronic diarrhea for at least 3 months prior to enrolment as evidenced by medical history
  10. Presence of stable chronic diarrhea during the 2-week screening diary period before randomization, as evidenced by completion of a screening diary demonstrating:

    1. Mean daily production of at least 3 soft or watery stools (BSFS scores 6 or 7); or
    2. More than 3 bowel movements per day on average with >25% of them being BSFS type 6 or 7
  11. Stated willingness and ability to comply with all study procedures, including daily recording of bowel movements and BSFS in the patient diaries, and availability for the duration of the study
  12. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without clinical significance, as determined by the investigator
  13. Female subjects must meet one of the following criteria:

    a) Participant is of and agrees to use one of the accepted regimens from at least 30 days prior to the first study treatment administration through to at least 30 days after the last dose of the study treatment. An acceptable method of contraception includes one of the following:

    1. Abstinence from heterosexual intercourse
    2. Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
    3. Intrauterine device (with or without hormones)
    4. Condom with spermicide

    b) Participants of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy or bilateral oophorectomy) or is in a menopausal state (i.e. at least 1 year without menses prior to the first study drug administration) are eligible

Exclusion criteria

Exclusion Criteria:

  1. Patients with known or suspected intestinal strictures of clinical relevance as judged by the Investigator
  2. Active inflammatory bowel disease (IBD) or fistula during the screening period as judged by the Investigator
  3. Crohn's disease patients not being in clinical remission for the last 12 weeks prior to randomization
  4. Diarrhea caused by other causes than SBS
  5. Presence of steatorrhea, requiring pancreatic enzymes supplementation
  6. Presence of complete biliary obstruction
  7. Presence of active cancer (except resected cutaneous basal or squamous cell carcinoma and except in situ cervical cancer) and/or need to receive chemotherapy or radiotherapy during the study
  8. History of allergic reaction to cholestyramine or any of the drug product or placebo, or packaging components
  9. Females who are lactating at screening
  10. Females who are pregnant according to the pregnancy test at screening or prior to the first study treatment administration
  11. Significant history (at least 3 consecutive months in the year prior to Screening) of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  12. Subjects who took an Investigational Product (IP) in the 30 days prior to the first study drug administration
  13. Any other clinically significant condition that is considered by the principal investigator as being susceptible to put the patient at greater safety risk, influence response to study product, or interfere with study assessments.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    "Low" Dose ECC Regimen

    ECC at the 1.7 g daily dose, administered BID (twice daily) as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.

    Drug: Enteric-Coated Cholestyramine (ECC) Capsule · Drug: Placebo

  • Experimental
    "High" Dose ECC Regimen

    ECC at the 4.25 g daily dose, administered BID (twice daily) as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.

    Drug: Enteric-Coated Cholestyramine (ECC) Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment

    Change in the weekly frequency of bowel movements measured between baseline and the second week of treatment. Baseline is defined as the second week of screening for treatment period 1 and second week of washout for treatment period 2.

    Time frame: Baseline and Week 2 of treatment (Days 8 to 14, and Days 36 to 42)

Secondary outcomes

  1. Total Number of Bowel Movements for the Whole 2-week Treatment Period

    Time frame: Days 1 to 14 and Days 29 to 42

  2. Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment

    The BSFS classifies the form of human feces into seven categories (Type 1 to Type 7) based on stool shape and consistency. Types or scores of 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 tending towards diarrhea, and 6 and 7 indicate diarrhea.

    Time frame: Days 8 to 14, and Days 36 to 42

  3. Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment

    Time frame: Days 8 to 14, and Days 36 to 42

07

Results

Posted Jul 19, 2022
Limitations and caveats
Early termination leading to small numbers of subjects analyzed and abbreviated statistical analyses.

Participant flow

First Intervention (14 Days)
Participant flow — First Intervention (14 Days)
Milestone"Low" Dose ECC Regimen, Then "High" Dose ECC Regimen"High" Dose ECC Regimen, Then "Low" Dose ECC Regimen
Started67
Completed67
Not completed00
Washout (14 Days)
Participant flow — Washout (14 Days)
Milestone"Low" Dose ECC Regimen, Then "High" Dose ECC Regimen"High" Dose ECC Regimen, Then "Low" Dose ECC Regimen
Started67
Completed67
Not completed00
Second Intervention (14 Days)
Participant flow — Second Intervention (14 Days)
Milestone"Low" Dose ECC Regimen, Then "High" Dose ECC Regimen"High" Dose ECC Regimen, Then "Low" Dose ECC Regimen
Started67
Completed67
Not completed00

Outcome measures

PrimaryChange in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment

Change in the weekly frequency of bowel movements measured between baseline and the second week of treatment. Baseline is defined as the second week of screening for treatment period 1 and second week of washout for treatment period 2.

Time frame:
Baseline and Week 2 of treatment (Days 8 to 14, and Days 36 to 42)
Reported as:
Mean · Weekly bowel movements
Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment
Weekly bowel movements"Low" Dose ECC Regimen"High" Dose ECC Regimen
Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment-11.5 ± 11.38-13.4 ± 9.73
SecondaryTotal Number of Bowel Movements for the Whole 2-week Treatment Period
Time frame:
Days 1 to 14 and Days 29 to 42
Reported as:
Mean · Bowel movements
Total Number of Bowel Movements for the Whole 2-week Treatment Period
Bowel movements"Low" Dose ECC Regimen"High" Dose ECC Regimen
Total Number of Bowel Movements for the Whole 2-week Treatment Period52.5 ± 20.1255.1 ± 25.18
SecondaryMean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment

The BSFS classifies the form of human feces into seven categories (Type 1 to Type 7) based on stool shape and consistency. Types or scores of 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 tending towards diarrhea, and 6 and 7 indicate diarrhea.

Time frame:
Days 8 to 14, and Days 36 to 42
Reported as:
Mean · Score on BSFS scale
Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment
Score on BSFS scale"Low" Dose ECC Regimen"High" Dose ECC Regimen
Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment3.6 ± 1.423.7 ± 1.76
SecondaryMean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment
Time frame:
Days 8 to 14, and Days 36 to 42
Reported as:
Mean · mg
Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment
mg"Low" Dose ECC Regimen"High" Dose ECC Regimen
Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment72.9 ± 43.0568.9 ± 53.19

Adverse events

Collected over From patient randomization to the end of study visit, approximately 44 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
"Low" Dose ECC Regimen0/13 (0%)0/13 (0%)3/13 (23.1%)
"High" Dose ECC Regimen0/13 (0%)0/13 (0%)4/13 (30.8%)
Most frequent other events
Most frequent other events
Event"Low" Dose ECC Regimen"High" Dose ECC Regimen
Abdominal pain upperGastrointestinal disorders1/131/13
Oedema peripheralGeneral disorders1/131/13
Pulpitis dentalInfections and infestations1/131/13
C-reactive protein increasedInvestigations0/131/13
HypokalaemiaMetabolism and nutrition disorders1/130/13
HypomagnesaemiaMetabolism and nutrition disorders0/131/13
Decreased appetiteMetabolism and nutrition disorders0/131/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intent-to-Treat (ITT Population)
Mean54.9 ± 15.98
Sex: Female, Male
Sex: Female, Male(Participants)Intent-to-Treat (ITT Population)
Female6
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Intent-to-Treat (ITT Population)
Asian0
Black0
Caucasian13
Other0
Region of Enrollment
Region of Enrollment(participants)Intent-to-Treat (ITT Population)
Poland13
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Intent-to-Treat (ITT Population)
Mean24.1 ± 3.84
08

Study locations

3 sites
  • Solumed Centrum Medyczne
    Poznań, Poland
  • Szpital Wielospecjalistyczny im. Stanleya Dudricka
    Skawina, Poland
  • Wojewódzki Specjalistyczny Szpital im. M. Pirogowa w Łodzi
    Łódź, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Dec 2021, 26 months.

Results were first posted in Jul 2022, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2019
First posted
Aug 6, 2019
StartActual
Oct 15, 2019
Primary completionActual
Dec 22, 2021
CompletionActual
Dec 22, 2021
Results first posted
Jul 19, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04046328
Lead sponsor
Pharmascience Inc.
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Oct 15, 2019
Primary completion
Dec 22, 2021
Completion
Dec 22, 2021
Results posted
Jul 19, 2022
Last update
Jul 19, 2022

Study contacts

Marek Kunecki, MD, PhD
principal investigator · Wojewódzki Specjalistyczny Szpital im. M. Pirogowa w Łodzi
Konrad Matysiak, MD, PhD
principal investigator · Solumed Centrum Medyczne
Kinga Szczepanek, MD
principal investigator · Szpital Wielospecjalistyczny im. Stanleya Dudricka

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cholestyramine Resin

Start the discussion